Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
|
Exhibit Number |
Description |
| 1.1 | Underwriting Agreement, dated September 27, 2017, by and among the Company, J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters named therein. |
| 5.1 | Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| 23.1 | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1). |
| 99.1 | Information relating to Item 14 of the Registration Statement on Form S-3 (File No.333-213495). |
| 99.2 | Press Release of Intra-Cellular Therapies, Inc., dated September 27, 2017. |
Intra-Cellular Therapies, Inc. ExhibitEX-1.1 2 d433570dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version INTRA-CELLULAR THERAPIES,…To view the full exhibit click here
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.
